Skip to main content
PMC home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2024 Jun;28(28):1–238. doi: 10.3310/YGWR4511

Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.

Beth Woods, Laetitia Schmitt, Dina Jankovic, Benjamin Kearns, Alison Scope, Shijie Ren, Tushar Srivastava, Chu Chang Ku, Jean Hamilton, Claire Rothery, Laura Bojke, Mark Sculpher, Sue Harnan
PMCID: PMC11229178  PMID: 38938145

Abstract

BACKGROUND

To limit the use of antimicrobials without disincentivising the development of novel antimicrobials, there is interest in establishing innovative models that fund antimicrobials based on an evaluation of their value as opposed to the volumes used. The aim of this project was to evaluate the population-level health benefit of cefiderocol in the NHS in England, for the treatment of severe aerobic Gram-negative bacterial infections when used within its licensed indications. The results were used to inform the National Institute for Health and Care Excellence guidance in support of commercial discussions regarding contract value between the manufacturer and NHS England.

METHODS

The health benefit of cefiderocol was first derived for a series of high-value clinical scenarios. These represented uses that were expected to have a significant impact on patients' mortality risks and health-related quality of life. The clinical effectiveness of cefiderocol relative to its comparators was estimated by synthesising evidence on susceptibility of the pathogens of interest to the antimicrobials in a network meta-analysis. Patient-level costs and health outcomes of cefiderocol under various usage scenarios compared with alternative management strategies were quantified using decision modelling. Results were reported as incremental net health effects expressed in quality-adjusted life-years, which were scaled to 20-year population values using infection number forecasts based on data from Public Health England. The outcomes estimated for the high-value clinical scenarios were extrapolated to other expected uses for cefiderocol.

RESULTS

Among Enterobacterales isolates with the metallo-beta-lactamase resistance mechanism, the base-case network meta-analysis found that cefiderocol was associated with a lower susceptibility relative to colistin (odds ratio 0.32, 95% credible intervals 0.04 to 2.47), but the result was not statistically significant. The other treatments were also associated with lower susceptibility than colistin, but the results were not statistically significant. In the metallo-beta-lactamase Pseudomonas aeruginosa base-case network meta-analysis, cefiderocol was associated with a lower susceptibility relative to colistin (odds ratio 0.44, 95% credible intervals 0.03 to 3.94), but the result was not statistically significant. The other treatments were associated with no susceptibility. In the base case, patient-level benefit of cefiderocol was between 0.02 and 0.15 quality-adjusted life-years, depending on the site of infection, the pathogen and the usage scenario. There was a high degree of uncertainty surrounding the benefits of cefiderocol across all subgroups. There was substantial uncertainty in the number of infections that are suitable for treatment with cefiderocol, so population-level results are presented for a range of scenarios for the current infection numbers, the expected increases in infections over time and rates of emergence of resistance. The population-level benefits varied substantially across the base-case scenarios, from 896 to 3559 quality-adjusted life-years over 20 years.

CONCLUSION

This work has provided quantitative estimates of the value of cefiderocol within its areas of expected usage within the NHS.

LIMITATIONS

Given existing evidence, the estimates of the value of cefiderocol are highly uncertain.

FUTURE WORK

Future evaluations of antimicrobials would benefit from improvements to NHS data linkages; research to support appropriate synthesis of susceptibility studies; and application of routine data and decision modelling to assess enablement value.

STUDY REGISTRATION

No registration of this study was undertaken.

FUNDING

This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment Policy Research Programme (NIHR award ref: NIHR135591), conducted through the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions, PR-PRU-1217-20401, and is published in full in Health Technology Assessment; Vol. 28, No. 28. See the NIHR Funding and Awards website for further award information.

Plain language summary

This project tested new methods for estimating the value to the NHS of an antimicrobial, cefiderocol, so its manufacturer could be paid fairly even if very little drug is used in order to reduce the risk of bacteria becoming resistant to the product. Clinicians said that the greatest benefit of cefiderocol is when used for complicated urinary tract infections and pneumonia acquired within hospitals caused by two types of bacteria (called Enterobacterales and Pseudomonas aeruginosa), with a resistance mechanism called metallo-beta-lactamase. Because there were no relevant clinical trial data, we estimated how effective cefiderocol and alternative treatments were by doing a systematic literature review of studies that grew bacteria from infections in the laboratory and tested the drugs on them. We linked this to data estimating the long-term health and survival of patients. Some evidence was obtained by asking clinicians detailed questions about what they thought the effects would be based on their experience and the available evidence. We included the side effects of the alternative treatments, some of which can cause kidney damage. We estimated how many infections there would be in the UK, whether they would increase over time and how resistance to treatments may change over time. Clinicians told us that they would also use cefiderocol to treat intra-abdominal and bloodstream infections, and some infections caused by another bacteria called Stenotrophomonas. We estimated how many of these infections there would be, and assumed the same health benefits as for other types of infections. The total value to the NHS was calculated using these estimates. We also considered whether we had missed any additional elements of value. We estimated that the value to the NHS was £18–71 million over 20 years. This reflects the maximum the NHS could pay for use of cefiderocol if the health lost as a result of making these payments rather than funding other NHS services is not to exceed the health benefits of using this antimicrobial. However, these estimates are uncertain due to limitations with the evidence used to produce them and assumptions that had to be made.

Full text of this article can be found in Bookshelf.

References

  1. Harnan SE, Woods B, Schmitt L, Kearns B, Srivastava T, Scope A, et al. Protocol for the technology evaluation of cefiderocol for treating severe aerobic Gram-negative bacterial infections. Health Technol Assess 2021. URL: www.nice.org.uk/guidance/hte2/history (accessed 21 February 2024). doi: 10.3310/YGWR4511. [DOI] [PMC free article] [PubMed]
  2. Hawkey PM, Warren RE, Livermore DM, McNulty CA, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob Chemother 2018;73(suppl_3):iii2–78. doi: 10.1093/jac/dky027. [DOI] [PubMed]
  3. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr 2016;4(2):1–24. doi: 10.1128/microbiolspec.VMBF-0016-2015. [DOI] [PMC free article] [PubMed]
  4. Hawkey PM. Multidrug-resistant Gram-negative bacteria: a product of globalization. J Hosp Infect 2015;89(4):241–7. doi: 10.1016/j.jhin.2015.01.008. [DOI] [PubMed]
  5. McNulty CAM, Boyle P, Nichols T, Clappison P, Davey P. Don’t wear me out – the public’s knowledge of and attitudes to antibiotic use. J Antimicrob Chemother 2007;59(4):727–38. doi: 10.1093/jac/dkl558. [DOI] [PubMed]
  6. Public Health England. English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2019 to 2020. London: UK Health Security Agency; 2020.
  7. Hughes S, Gilchrist M, Heard K, Hamilton R, Sneddon J. Treating infections caused by carbapenemase-producing Enterobacterales (CPE): a pragmatic approach to antimicrobial stewardship on behalf of the UKCPA Pharmacy Infection Network (PIN). JAC-Antimicrob Resist 2020;2(3):dlaa075. doi: 10.1093/jacamr/dlaa075. [DOI] [PMC free article] [PubMed]
  8. World Health Organization. WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. Geneva, Switzerland: World Health Organization; 2017.
  9. World Health Organization. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Geneva, Switzerland: World Health Organization; 2017.
  10. Tan X, Kim HS, Baugh K, Huang Y, Kadiyala N, Wences M, et al. Therapeutic options for metallo-β-lactamase-producing Enterobacterales. Infect Drug Resist 2021;14:125–42. doi: 10.2147/IDR.S246174. [DOI] [PMC free article] [PubMed]
  11. Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, et al. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 2016;71(3):670–7. doi: 10.1093/jac/dkv402. [DOI] [PubMed]
  12. Ito A, Nishikawa T, Matsumoto S, Yoshizawa H, Sato T, Nakamura R, et al. Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2016;60(12):7396–401. doi: 10.1128/AAC.01405-16. [DOI] [PMC free article] [PubMed]
  13. Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2018;18(12):1319–28. doi: 10.1016/S1473-3099(18)30554-1. [DOI] [PubMed]
  14. Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2021;21(2):213–25. doi: 10.1016/S1473-3099(20)30731-3. [DOI] [PubMed]
  15. Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021;21(2):226–40. doi: 10.1016/S1473-3099(20)30796-9. [DOI] [PubMed]
  16. Tsuji M, Hackel M, Echols R, Yamano Y, Sahm DF. In Vitro Activity of Cefiderocol Against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Tract Source: SIDERO-CR-2014/2016. Poster presented at: IDWeek, Arlington, VA, 2017.
  17. Nguyen S, editor. In Vitro Antibacterial Activity of Cefiderocol against a Multi-National Collection of Carbapenem Non-Susceptible Gram-Negative Bacteria Isolated from Respiratory, Blood, Skin/Soft Tissue and Urinary Sources of Infection: SIDERO-WT-2014-2017. New Orleans, LA: ASM; 2017.
  18. Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, et al. Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli. Drugs 2019;79(3):271–89. doi: 10.1007/s40265-019-1055-2. [DOI] [PubMed]
  19. Shionogi. European Medicines Agency. Annex I: Summary of Product Characteristics Fetcroja 1g. URL: https://ema.europa.eu/en/documents/product-information/fetcroja-epar-product-information_en.pdf (accessed 16 May 2024).
  20. National Institute for Health and Care Excellence. Cefiderocol for Treating Severe Drug-Resistant Gram-Negative Bacterial Infections. London. URL: www.nice.org.uk/about/what-we-do/life-sciences/scientific-advice/models-for-the-evaluation-and-purchase-of-antimicrobials/cefiderocol (accessed 16 May 2024).
  21. Rothery C, Woods B, Schmitt L, Claxton K, Palmer S, Sculpher M. Framework for Value Assessment of New Pharmaceuticals: Implications of Alternative Funding Arrangements for NICE Appraisal. EEPRU; 2018. URL: www.eepru.org.uk/article/framework-for-value-assessment-of-new-antimicrobials-implications-of-alternative-funding-arrangements-for-nice-appraisal/ (accessed 16 May 2024).
  22. Public Health England. Framework of Actions to Contain Carbapenemase-Producing Enterobacterales. London: Public Health England; 2020.
  23. Public Health England. UK Standards for Microbiology Investigations: Detection of Bacteria with Carbapenem-hydrolysing β-lactamases (Carbapenemases). London: Public Health England; 2020.
  24. European Committee on Antimicrobial Susceptibility Testing. Standard Operating Procedure: Setting Breakpoints for New Antimicrobial Agents. 2019. URL: www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/EUCAST_SOPs/EUCAST_SOP_1.3_Setting_breakpoints_new_agents_20191023.pdf (accessed 16 May 2024).
  25. Harnan SE, Cooper K, Jones SL, Jones E. Pruning and prioritising: a case study of a pragmatic method for managing a rapid systematic review with limited resources. Evid Policy J Res Debate Pract 2015;11(4):589–601.
  26. Uttley L, Whiteman BL, Woods HB, Harnan S, Philips ST, Cree IA; Early Cancer Detection Consortium. Building the evidence base of blood-based biomarkers for early detection of cancer: a rapid systematic mapping review. EBioMedicine 2016;10:164–73. doi: 10.1016/j.ebiom.2016.07.004. [DOI] [PMC free article] [PubMed]
  27. Kaltenthaler E, Tappenden P, Paisley S, Squires H. NICE DSU Technical Support Document 13: Identifying and Reviewing Evidence to Inform the Conceptualisation and Population of Cost-Effectiveness Models. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2011. [PubMed]
  28. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012;65:934–39. doi: 10.1016/j.jclinepi.2011.11.014. [DOI] [PubMed]
  29. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Chapter 5: Systematic reviews of prevalence and incidence. In Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI Manual for Evidence Synthesis. JBI; 2024. URL: https://synthesismanual.jbi.global (accessed 16 May 2024).
  30. Hinneburg I. ROBINS-1: a tool for assessing risk of bias in non-randomised studies of interventions. Med Monatsschr Pharm 2017;40(4):175–7. [PubMed]
  31. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. doi: 10.1136/bmj.l4898. [DOI] [PubMed]
  32. Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011.
  33. Shionogi. Candor Simulation – Retrospective Analysis of Cefiderocol and Comparators by Population PK/PD Simulation. Shionogi data on file. 2021.
  34. Shionogi. Response to EEPRU’s Data Request Relating to SIDERO-WT. 2021. URL: www.nice.org.uk/guidance/hte2/documents/agenda-4 (accessed 28 February 2024).
  35. Shionogi. Response to EEPRU’s Data Request Relating to SIDERO-CR. 2021. URL: www.nice.org.uk/guidance/hte2/documents/agenda-4 (accessed 28 February 2024).
  36. Albano M, Karau MJ, Schuetz AN, Patel R. Comparison of agar dilution to broth microdilution for testing in vitro activity of cefiderocol against Gram-negative Bacilli. J Clin Microbiol 2020;59(1):17. doi: 10.1128/JCM.00966-20. [DOI] [PMC free article] [PubMed]
  37. Biagi M, Vialichka A, Jurkovic M, Wu T, Shajee A, Lee M, et al. Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2020;64(9):e00559-20. doi: 10.1128/AAC.00559-20. [DOI] [PMC free article] [PubMed]
  38. Delgado-Valverde M, Del Carmen Conejo M, Serrano L, Fernandez-Cuenca F, Pascual A. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother 2020;75(7):1840–9. doi: 10.1093/jac/dkaa117. [DOI] [PMC free article] [PubMed]
  39. Ghazi IM, Monogue ML, Tsuji M, Nicolau DP. Humanized exposures of cefiderocol, a siderophore cephalosporin, display sustained in vivo activity against siderophore-resistant Pseudomonas aeruginosa. Pharmacology 2018;101(5–6):278–84. doi: 10.1159/000487441. [DOI] [PMC free article] [PubMed]
  40. Ghazi IM, Monogue ML, Tsuji M, Nicolau DP. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model. Int J Antimicrob Agents 2018;51(2):206–12. doi: 10.1016/j.ijantimicag.2017.10.008. [DOI] [PubMed]
  41. Golden AR, Adam HJ, Baxter M, Walkty A, Lagace-Wiens P, Karlowsky JA, Zhanel GG. In vitro activity of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacilli isolated from patients in Canadian Intensive Care Units. Diagn Microbiol Infect Dis 2020;97(1):115012. doi: 10.1016/j.diagmicrobio.2020.115012. [DOI] [PubMed]
  42. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 2018;62(2):e01968–17. doi: 10.1128/AAC.01968-17. [DOI] [PMC free article] [PubMed]
  43. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. Diagn Microbiol Infect Dis 2019;94(4):321–5. doi: 10.1016/j.diagmicrobio.2019.03.003. [DOI] [PubMed]
  44. Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahma DF. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative Bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study). Antimicrob Agents Chemother 2017;61(9):e00093-17. doi: 10.1128/AAC.00093-17. [DOI] [PMC free article] [PubMed]
  45. Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother 2019;74(2):380–6. doi: 10.1093/jac/dky425. [DOI] [PubMed]
  46. Huband MD, Ito A, Tsuji M, Sader HS, Fedler KA, Flamm RK. Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design. Diagn Microbiol Infect Dis 2017;88(2):198–200. doi: 10.1016/j.diagmicrobio.2017.03.011. [DOI] [PubMed]
  47. Iregui A, Khan Z, Landman D, Quale J. Activity of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii endemic to medical centers in New York City. Microb Drug Resist 2020;26(7):722–6. doi: 10.1089/mdr.2019.0298. [DOI] [PMC free article] [PubMed]
  48. Ito A, Nishikawa T, Ota M, Ito-Horiyama T, Ishibashi N, Sato T, et al. Stability and low induction propensity of cefiderocol against chromosomal AmpC b-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae. J Antimicrob Chemother 2018;73(11):3049–52. doi: 10.1093/jac/dky317. [DOI] [PMC free article] [PubMed]
  49. Johnston BD, Thuras P, Porter SB, Clabots C, Johnsona JR. Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-20017) in relation to phylogenetic background, sequence type 131 subclones, blaCTX-M genotype, and coresistance. Diagn Microbiol Infect Dis 2021;100(1):115314. doi: 10.1016/j.diagmicrobio.2021.115314. [DOI] [PubMed]
  50. Karlowsky JA, Hackel MA, Tsuji M, Yamano Y, Echols R, Sahm DF. In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative Bacilli isolated by clinical laboratories in North America and Europe in 2015–2016: SIDERO-WT-2015. Int J Antimicrob Agents 2019;53(4):456–66. doi: 10.1016/j.ijantimicag.2018.11.007. [DOI] [PubMed]
  51. Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol 2017;57(5):584–91. doi: 10.1002/jcph.841. [DOI] [PMC free article] [PubMed]
  52. Katsube T, Echols R, Wajima T. Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin. Clin Infect Dis 2019;69(Suppl. 7):S552–8. doi: 10.1093/cid/ciz828. [DOI] [PMC free article] [PubMed]
  53. Katsube T, Saisho Y, Shimada J, Furuie H. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects. J Antimicrob Chemother 2019;74(7):1971–4. doi: 10.1093/jac/dkz123. [DOI] [PMC free article] [PubMed]
  54. Kawaguchi N, Katsube T, Echols R, Wajima T. Population pharmacokinetic analysis of cefiderocol, a parenteral siderophore cephalosporin, in healthy subjects, subjects with various degrees of renal function, and patients with complicated urinary tract infection or acute uncomplicated pyelonephritis. Antimicrob Agents Chemother 2018;62(2):e01391-17. doi: 10.1128/AAC.01391-17. [DOI] [PMC free article] [PubMed]
  55. Kawaguchi N, Katsube T, Echols R, Wajima T. Population pharmacokinetic and pharmacokinetic/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection/sepsis, or complicated urinary tract infection. Antimicrob Agents Chemother 2021;65(3):17. doi: 10.1128/AAC.01437-20. [DOI] [PMC free article] [PubMed]
  56. Kawai A, McElheny CL, Iovleva A, Kline EG, Sluis-Cremer N, Shields RK, Doi Y. Structural basis of reduced susceptibility to ceftazidime-avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion. Antimicrob Agents Chemother 2020;64(7):e00198-20. doi: 10.1128/AAC.00198-20. [DOI] [PMC free article] [PubMed]
  57. Matsumoto S, Singley CM, Hoover J, Nakamura R, Echols R, Rittenhouse S, et al. Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother 2017;61(9):e00700-17. doi: 10.1128/AAC.00700-17. [DOI] [PMC free article] [PubMed]
  58. Nath S, Moussavi F, Abraham D, Landman D, Quale J. In vitro and in vivo activity of single and dual antimicrobial agents against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother 2018;73(2):431–6. doi: 10.1093/jac/dkx419. [DOI] [PubMed]
  59. Paul Morris C, Bergman Y, Tekle T, Fissel JA, Tamma PD, Simner PJ. Cefiderocol antimicrobial susceptibility testing against multidrug-resistant Gram-negative bacilli: a comparison of disk diffusion to broth microdilution. J Clin Microbiol 2021;59(1):e01649-20. doi: 10.1128/JCM.01649-20. [DOI] [PMC free article] [PubMed]
  60. Pybus CA, Felder-Scott C, Obuekwe V, Greenberg DE. Cefiderocol retains antibiofilm activity in multidrug-resistant Gram-negative pathogens. Antimicrob Agents Chemother 2021;65(2):e01194-20. doi: 10.1128/AAC.01194-20. [DOI] [PMC free article] [PubMed]
  61. Pybus CA, Greenberg DE. Cefiderocol retains anti-biofilm activity in MDR Gram-negative pathogens. Open Forum Infect 2019;6(Suppl. 2):S323–4.
  62. Rolston KVI, Gerges B, Shelburne S, Aitken SL, Raad I, Prince RA. Activity of cefiderocol and comparators against isolates from cancer patients. Antimicrob Agents Chemother 2020;64(5):e01955-19. doi: 10.1128/AAC.01955-19. [DOI] [PMC free article] [PubMed]
  63. Sanabria C, Migoya E, Mason JW, Stanworth SH, Katsube T, Machida M, et al. Effect of cefiderocol, a siderophore cephalosporin, on QT/QTc interval in healthy adult subjects. Clin Ther 2019;41(9):1724–36.e4. doi: 10.1016/j.clinthera.2019.07.006. [DOI] [PubMed]
  64. Sato T, Ito A, Ishioka Y, Matsumoto S, Rokushima M, Kazmierczak KM, et al. Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study. JAC-Antimicrob Resist 2020;2(3):dlaa081. doi: 10.1093/jacamr/dlaa081. [DOI] [PMC free article] [PubMed]
  65. Talan DA, Takhar SS, Krishnadasan A, Mower WR, Pallin DJ, Garg M, et al. Emergence of extended-spectrum beta-lactamase urinary tract infections among hospitalized emergency department patients in the United States. Ann Emerg Med 2021;77(1):32–43. doi: 10.1016/j.annemergmed.2020.08.022. [DOI] [PubMed]
  66. Tsiplakou S, Papaioannou V, Trikka-Graphakos E, Charalampakis N, Sereti C, Lebessi E, et al. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother 2017;72(6):1704–8. doi: 10.1093/jac/dkx049. [DOI] [PubMed]
  67. Dobias J, Denervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens. Eur J Clin Microbiol Infect Dis 2017;36(12):2319–27. doi: 10.1007/s10096-017-3063-z. [DOI] [PubMed]
  68. Jacobs MR, Abdelhamed AM, Good CE, Rhoads DD, Hujer KM, Hujer AM, et al. ARGONAUT-I: Activity of cefiderocol (s-649266), a siderophore cephalosporin, against Gram-negative bacteria, including carbapenem-resistant nonfermenters and Enterobacteriaceae with defined extended-spectrum beta-lactamases and carbapenemases. Antimicrob Agents Chemother 2019;63(1):e01801-18. doi: 10.1128/AAC.01801-18. [DOI] [PMC free article] [PubMed]
  69. Mushtaq S, Sadouki Z, Vickers A, Livermore DM, Woodford N. In vitro activity of cefiderocol, a siderophore cephalosporin, against multidrug-resistant Gram-negative bacteria. Antimicrob Agents Chemother 2020;64(12):e01582-20. doi: 10.1128/AAC.01582-20. [DOI] [PMC free article] [PubMed]
  70. Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 2018;62(1):e01454-17. doi: 10.1128/AAC.01454-17. [DOI] [PMC free article] [PubMed]
  71. Kresken M, Korte-Berwanger M, Gatermann SG, Pfeifer Y, Pfennigwerth N, Seifert H, Werner G. In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany. Int J Antimicrob Agents 2020;56(4):106128. doi: 10.1016/j.ijantimicag.2020.106128. [DOI] [PubMed]
  72. Bleibtreu A, Dortet L, Bonnin RA, Wyplosz B, Sacleux SC, Mihaila L, et al. Susceptibility testing is key for the success of cefiderocol treatment: a retrospective Cohort study. Microorganisms 2021;9(2):282. doi: 10.3390/microorganisms9020282. [DOI] [PMC free article] [PubMed]
  73. Falcone M, Tiseo G, Nicastro M, Leonildi A, Vecchione A, Casella C, et al. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in ICU patients. Clin Infect Dis 2020;17(11):2021–4. doi: 10.1093/cid/ciaa1410. [DOI] [PubMed]
  74. Haller S, Kramer R, Becker K, Bohnert JA, Eckmanns T, Hans JB, et al. Extensively drug-resistant Klebsiella pneumoniae ST307 outbreak, north-eastern Germany, June to October 2019. Euro Surveill 2019;24(50):1900734. doi: 10.2807/1560-7917.ES.2019.24.50.1900734. [DOI] [PMC free article] [PubMed]
  75. Oliva A, Ceccarelli G, De Angelis M, Sacco F, Miele MC, Mastroianni CM, Venditti M. Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii. J Glob Antimicrob Resist 2020;23:292–6. doi: 10.1016/j.jgar.2020.09.019. [DOI] [PubMed]
  76. Shields RK, Iovleva A, Kline EG, Kawai A, McElheny CL, Doi Y. Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime. Clin Infect Dis 2020;71(10):2713–6. doi: 10.1093/cid/ciaa355. [DOI] [PMC free article] [PubMed]
  77. Zingg S, Nicoletti GJ, Kuster S, Junker M, Widmer A, Egli A, et al. Cefiderocol for extensively drug-resistant Gram-negative bacterial infections: real-world experience from a case series and review of the literature. Open Forum Infect 2020;7(6):ofaa185. doi: 10.1093/ofid/ofaa185. [DOI] [PMC free article] [PubMed]
  78. Johnston BD, Thuras P, Porter SB, Anacker M, VonBank B, Vagnone PS, et al. Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against carbapenem-resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, coresistance, and region. Antimicrob Agents Chemother 2020;64(10):e00797-20. doi: 10.1128/AAC.00797-20. [DOI] [PMC free article] [PubMed]
  79. Kazmierczak KM, Tsuji M, Wise MG, Hackel M, Yamano Y, Echols R, Sahm DF. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-beta-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents 2019;53(2):177–84. doi: 10.1016/j.ijantimicag.2018.10.007. [DOI] [PubMed]
  80. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 2016;60(2):729–34. doi: 10.1128/AAC.01695-15. [DOI] [PMC free article] [PubMed]
  81. Longshaw C, Manissero D, Tsuji M, Echols R, Yamano Y. In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe. JAC Antimicrob Resist 2020;2(3):dlaa060. doi: 10.1093/jacamr/dlaa060. [DOI] [PMC free article] [PubMed]
  82. Shionogi. National Institute of Health and Care Excellence, Antimicrobial Health Technology Evaluation: Cefiderocol for Treating Severe Aerobic Gram-Negative Bacterial Infections. Company evidence submission. URL: www.nice.org.uk/guidance/hte2/history (accessed 21 February 2024).
  83. Chakraborty T, Sadek M, Yao Y, Imirzalioglu C, Stephan R, Poirel L, Nordmann P. Cross-border emergence of Escherichia coli producing the carbapenemase NDM-5 in Switzerland and Germany. J Clin Microbiol 2021;59(3):e02238-20. doi: 10.1128/JCM.02238-20. [DOI] [PMC free article] [PubMed]
  84. Kaase M, Pfennigwerth N, Lange F, Anders A, Gatermann SG. Molecular epidemiology of VIM-1 producing Escherichia coli from Germany referred to the National Reference Laboratory. Int J Med Microbiol 2015;305(7):784–9. doi: 10.1016/j.ijmm.2015.08.032. [DOI] [PubMed]
  85. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011;37(5):415–9. doi: 10.1016/j.ijantimicag.2011.01.012. [DOI] [PubMed]
  86. Ojdana D, Gutowska A, Sacha P, Majewski P, Wieczorek P, Tryniszewska E. Activity of ceftazidime-avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae. Microb Drug Resist 2019;25(9):1357–64. doi: 10.1089/mdr.2018.0234. [DOI] [PubMed]
  87. Perry JD, Naqvi SH, Mirza IA, Alizai SA, Hussain A, Ghirardi S, et al. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J Antimicrob Chemother 2011;66(10):2288–94. doi: 10.1093/jac/dkr299. [DOI] [PubMed]
  88. Cuba GT, Rocha-Santos G, Cayô R, Streling AP, Nodari CS, Gales AC, et al. In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa. J Antimicrob Chemother 2020;75(7):1874–8. doi: 10.1093/jac/dkaa095. [DOI] [PubMed]
  89. Aires CA, Pereira PS, de Araujo CF, Chagas TP, Oliveira JC, Buonora SN, et al. Multiclonal expansion of Klebsiella pneumoniae isolates producing NDM-1 in Rio de Janeiro, Brazil. Antimicrob Agents Chemother 2017;61(4):e01048-16. doi: 10.1128/AAC.01048-16. [DOI] [PMC free article] [PubMed]
  90. Sonnevend A, Ghazawi A, Darwish D, Barathan G, Hashmey R, Ashraf T, et al. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula. Int J Infect Dis 2020;99:253–9. doi: 10.1016/j.ijid.2020.07.050. [DOI] [PubMed]
  91. Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, et al. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gram-negative Bacilli. Antimicrob Agents Chemother 2015;59(12):7842–6. doi: 10.1128/AAC.02019-15. [DOI] [PMC free article] [PubMed]
  92. Jahan S, Davis H, Ashcraft DS, Pankey GA. Evaluation of the in vitro interaction of fosfomycin and meropenem against metallo-β-lactamase-producing Pseudomonas aeruginosa using Etest and time-kill assay. J Investig Med 2021;69(2):371–6. doi: 10.1136/jim-2020-001573. [DOI] [PubMed]
  93. Public Health England. English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2018 to 2019. London: Public Health England; 2020.
  94. Kohira N, Hackel MA, Ishioka Y, Kuroiwa M, Sahm DF, Sato T, et al. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist 2020;22:738–41. doi: 10.1016/j.jgar.2020.07.009. [DOI] [PubMed]
  95. European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 11.0. 2021. URL: www.eucast.org. www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf (accessed 22 October 2021).
  96. Brown DFJ, Wootton M, Howe RA. Antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST. J Antimicrob Chemother 2015;71(1):3–5. doi: 10.1093/jac/dkv287. [DOI] [PubMed]
  97. Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials. London: National Institute for Health and Care Excellence (NICE); 2014. [PubMed]
  98. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials. Sheffield, UK: NICE Decision Support Unit; 2011. [PubMed]
  99. Daly C, Downing BC, Welton NJ. A Practical Guide to Inconsistency Checks in Bayesian Network Meta-analysis. Bristol, UK: NICE Guidelines Technical Support Unit. URL: www.bristol.ac.uk/media-library/sites/social-community-medicine/documents/mpes/Guide%20to%20Checking%20for%20Inconsistency%20in%20NMA_TSU.pdf (accessed 29 August 2023).
  100. EUnetHTA. Authoring Team. Cefiderocol (Fetcroja®) for the Treatment of Infections Due to Aerobic Gram-negative Organisms in Adults with Limited Treatment Options. Joint Assessment. Report No. PTJA11. Diemen, The Netherlands: EUnetHTA; 2020. p. 122. URL: www.eunethta.eu (accessed 16 May 2024).
  101. Bassetti M, Echols R, Matsunaga Y, Portsmouth S, Ariyasu M, Toyoizumi K, et al. Efficacy and safety of cefiderocol and best available therapy in patients with serious infections caused by carbapenem-resistant Gram-negative infections: results of the pathogen-focused phase 3 CREDIBLE-CR study. Open Forum Infect 2020;7(Suppl. 1):S652–3.
  102. Bassetti M, Ariyasu M, Binkowitz B, Nagata TD, Echols RM, Matsunaga Y, et al. Designing a pathogen-focused study to address the high unmet medical need represented by carbapenem-resistant Gram-negative pathogens – the international, multicenter, randomized, open-label, phase 3 CREDIBLE-CR study. Infect Drug Resist 2019;12:3607–23. doi: 10.2147/IDR.S225553. [DOI] [PMC free article] [PubMed]
  103. Mushtaq S, Sadouki Z, Vickers A, Livermore D, Woodford N. In-vitro activity of cefiderocol against multidrug-resistant Enterobacterales, Pseudomonas aeruginosa and Acinetobacter baumannii isolates from the UK. Access Microbiology 2020;2(2):50.
  104. Mushtaq S, Sadouki Z, Vickers A, Livermore DM, Woodford N. In Vitro Activity of Cefiderocol against Extensively Drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii from the UK. 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, 2019.
  105. Bojke L, Soares M, Claxton K, Colson A, Fox A, Jackson C, et al. Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study. Health Technol Assess (Winchester, England) 2021;25(37):1–124. doi: 10.3310/hta25370. [DOI] [PMC free article] [PubMed]
  106. Chang W, Cheng J, Allaire J, Xie Y, McPherson J. Package ‘Shiny’. 2015. URL: https://cran.r-project.org/web/packages/shiny/index.htm (accessed 16 May 2024).
  107. O’Hagan A, Buck CE, Daneshkhah A, Eiser JR, Garthwaite PH, Jenkinson DJ, et al. Uncertain Judgements: Eliciting Experts’ Probabilities. Chichester, UK: John Wiley 2006.
  108. Lopes S, Franceschini M, Han Y, Green W, Dymond A, Gill A. Economic Evaluation of Cefiderocol for the Treatment of Carbapenem Resistant Infections in the United States. AMCP Nexus 2020 Virtual, 19–23 October 2020. Poster, 2020.
  109. Tichy E, Torres A, Bassetti M, Kongnakorn T, Di Virgilio R, Irani P, Charbonneau C. Cost-effectiveness comparison of ceftazidime/avibactam versus meropenem in the empirical treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, in Italy. Clin Ther 2020;42(5):802–17. doi: 10.1016/j.clinthera.2020.03.014. [DOI] [PubMed]
  110. Kongnakorn T, Wagenlehner F, Falcone M, Tichy E, Di Virgilio R, Baillon-Plot N, Charbonneau C. Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections. Int J Antimicrob Agents 2019;54(5):633–41. doi: 10.1016/j.ijantimicag.2019.06.008. [DOI] [PubMed]
  111. Nguyen CP, Dan Do TN, Bruggemann R, Ten Oever J, Kolwijck E, Adang EMM, Wertheim HF. Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis. Int J Antimicrob Agents 2019;54(6):790–7. doi: 10.1016/j.ijantimicag.2019.07.003. [DOI] [PubMed]
  112. Simon MS, Sfeir MM, Calfee DP, Satlin MJ. Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia. Antimicrob Agents Chemother 2019;63:23. doi: 10.1128/AAC.00897-19. [DOI] [PMC free article] [PubMed]
  113. Chen GJ, Pan SC, Foo J, Morel C, Chen WT, Wang JT. Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: a cost-utility model focusing on Gram-negative bacteria. J Microbiol Immunol Infect 2019;52(5):807–15. doi: 10.1016/j.jmii.2019.04.003. [DOI] [PubMed]
  114. Mewes JC, Pulia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM. The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: a health economic model analysis. PLOS ONE 2019;14(4):e0214222. doi: 10.1371/journal.pone.0214222. [DOI] [PMC free article] [PubMed]
  115. Nelson RE, Ray W, Rubin MA, Schweizer M. Evaluating the Cost-effectiveness of Decolonization for Prevention of MRSA Infections using a Dynamic Transmission Model. Vol. 8, Suppl. 1. Antimicrobial Resistance and Infection Control Conference: 5th International Conference on Prevention and Infection Control, ICPIC 2019.
  116. Gordon J, Darlington O, McEwan P, Lumley M, Taie A, Hicks M, et al. Estimating the value of new antimicrobials in the context of antimicrobial resistance: development and application of a dynamic disease transmission model. PharmacoEcon 2020;38(8):857–69. doi: 10.1007/s40273-020-00906-6. [DOI] [PubMed]
  117. Wagner AP, Enne VI, Livermore DM, Craig JV, Turner DA; INHALE Study Group. Review of health economic models exploring and evaluating treatment and management of hospital-acquired pneumonia and ventilator-associated pneumonia. J Hosp Infect 2020;106(4):745–56. doi: 10.1016/j.jhin.2020.09.012. [DOI] [PubMed]
  118. Edwards SJ, Wordsworth S, Clarke MJ. Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam. Eur J Health Econ 2012;13:181–92. doi: 10.1007/s10198-011-0296-0. [DOI] [PubMed]
  119. Grau S, Alvarez-lerma F, del Castillo A, Neipp R, Rubio-terrés C. Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain. J Chemother 2005;17:203–11. doi: 10.1179/joc.2005.17.2.203. [DOI] [PubMed]
  120. Kongnakorn T, Mwamburi M, Merchant S, Akhras K, Caro JJ, Nathwani D. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. Curr Med Res Opin 2010;26:17–24. doi: 10.1185/03007990903358980. [DOI] [PubMed]
  121. Kauf TL, Prabhu VS, Medic G, Borse RH, Miller B, Gaultney J, et al. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections. BMC Infect Dis 2017;17(1):314. doi: 10.1186/s12879-017-2408-7. [DOI] [PMC free article] [PubMed]
  122. Schaffer SK, West P, Towse A, Henshall C, Mestre-Ferrandiz J, Masterton R, et al. Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions. London: Office of Health Economics; 2017.
  123. Medicines and Healthcare products Regulatory Agency. Aminoglycosides (Gentamicin, Amikacin, Tobramycin, and Neomycin): Increased Risk of Deafness in Patients with Mitochondrial Mutations. GOV.UK; 2021. URL: www.gov.uk/drug-safety-update/aminoglycosides-gentamicin-amikacin-tobramycin-and-neomycin-increased-risk-of-deafness-in-patients-with-mitochondrial-mutations (accessed 16 May 2024).
  124. Pfizer. National Institute of Health and Care Excellence, Antimicrobial Health Technology Evaluation: Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections. Company evidence submission. URL: www.nice.org.uk/guidance/hte1/history (accessed 21 February 2024).
  125. Tumbarello M, De Pascale G, Trecarichi EM, Spanu T, Antonicelli F, Maviglia R, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 2013;39(4):682–92. doi: 10.1007/s00134-013-2828-9. [DOI] [PubMed]
  126. Mushtaq S, Garello P, Vickers A, Woodford N, Livermore DM. Activity of cefepime/zidebactam (WCK 5222) against ‘problem’ antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. J Antimicrob Chemother 2021;76:1511–22. doi: 10.1093/jac/dkab067. [DOI] [PubMed]
  127. Livermore DM, Nicolau DP, Hopkins KL, Meunier D. Carbapenem-resistant Enterobacterales, carbapenem resistant organisms, carbapenemase-producing Enterobacterales, and carbapenemase-producing organisms: terminology past its ‘sell-by date’ in an era of new antibiotics and regional carbapenemase epidemiology. Clin Infect Dis 2020;71(7):1776–82. doi: 10.1093/cid/ciaa122. [DOI] [PubMed]
  128. Sisay M, Hagos B, Edessa D, Tadiwos Y, Mekuria AN. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res 2021;163:105328. doi: 10.1016/j.phrs.2020.105328. [DOI] [PubMed]
  129. Chien H-T, Lin Y-C, Sheu C-C, Hsieh K-P, Chang J-S. Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis. Int J Antimicrob Agents 2020;55(3):105889. doi: 10.1016/j.ijantimicag.2020.105889. [DOI] [PubMed]
  130. Kerr M, Bedford M, Matthews B, O’Donoghue D. The economic impact of acute kidney injury in England. Nephrol Dial Transplant 2014;29(7):1362–8. doi: 10.1093/ndt/gfu016. [DOI] [PubMed]
  131. Wagenlehner F, Lucenteforte E, Pea F, Soriano A, Tavoschi L, Steele VR, et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect 2021;27(5):671–86. doi: 10.1016/j.cmi.2020.12.009. [DOI] [PubMed]
  132. Oliota AF, Penteado ST, Tonin FS, Fernandez-Llimos F, Sanches AC. Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies. Diagn Microbiol Infect Dis 2019;94(1):41–9. doi: 10.1016/j.diagmicrobio.2018.11.008. [DOI] [PubMed]
  133. Palacios-Baena ZR, Giannella M, Manissero D, Rodríguez-Baño J, Viale P, Lopes S, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clin Microbiol Infect 2020;27:228–35. doi: 10.1016/j.cmi.2020.10.016. [DOI] [PubMed]
  134. Open VIE Ltd. UK Draft Study Report. CARBAR. A retrospective study to evaluate the epidemiology, standard of care, outcomes and resource use associated with patients who have or are at risk of, infection with carbapenem non-susceptible Gram-negative organisms of interest (Enterobacterales, Pseudomonas spp., Stenotrophomonas spp. and Acinetobacter spp.). 2020.
  135. Merrick B, Tan MKI, Bisnauthsing K, Goldenberg SD. Healthcare resource use in hospitalized patients with carbapenem-resistant Gram-negative infections. J Hosp Infect 2021;110:7–14. doi: 10.1016/j.jhin.2020.12.021. [DOI] [PubMed]
  136. Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012;12(1):1–13. doi: 10.1186/1471-2288-12-9. [DOI] [PMC free article] [PubMed]
  137. Latimer N. NICE DSU Technical Support Document 14: Survival Analysis For Economic Evaluations Alongside Clinical Trials – Extrapolation With Patient-Level Data NICE Decision Support Unit. 2011.URL: https://ncbi.nlm.nih.gov/books/NBK395885/pdf/Bookshelf_NBK395885.pdf (accessed 8 February 2024).
  138. Bucaloiu ID, Kirchner HL, Norfolk ER, Hartle JE, II, Perkins RM. Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury. Kidney Int 2012;81(5):477–85. doi: 10.1038/ki.2011.405. [DOI] [PubMed]
  139. Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health 2010;13(5):509–18. doi: 10.1111/j.1524-4733.2010.00700.x. [DOI] [PubMed]
  140. Hadjiat Y, Serrie A, Treves R, Chomier B, Geranton L, Billon S. Pain associated with health and economic burden in France: results from recent National Health and Wellness Survey data. ClinicoEcon 2018;10:53–65. doi: 10.2147/CEOR.S148405. [DOI] [PMC free article] [PubMed]
  141. Wyld M, Morton RL, Hayen A, Howard K, Webster AC. A systematic review and meta-analysis of utility-based quality of life in chronic kidney disease treatments. PLOS Med 2012;9:e1001307. doi: 10.1371/journal.pmed.1001307. [DOI] [PMC free article] [PubMed]
  142. Kerr M, Bray B, Medcalf J, O’Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant 2012;27(suppl_3):iii73–80. doi: 10.1093/ndt/gfs269. [DOI] [PMC free article] [PubMed]
  143. Muscedere JG, Shorr AF, Jiang X, Day A, Heyland DK. The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. J Crit Care 2012;27(3):322.e7–322.e14. doi: 10.1016/j.jcrc.2011.09.004. [DOI] [PubMed]
  144. Kolhe NV, Eldehni MT, Selby NM, McIntyre CW. The reimbursement and cost of acute kidney injury: a UK hospital perspective. Nephron Clin Pract 2014;126(1):51–6. doi: 10.1159/000358435. [DOI] [PubMed]
  145. Knight GM, Costelloe C, Deeny SR, Moore LSP, Hopkins S, Johnson AP, et al. Quantifying where human acquisition of antibiotic resistance occurs: a mathematical modelling study. BMC Med 2018;16(1):137. doi: 10.1186/s12916-018-1121-8. [DOI] [PMC free article] [PubMed]
  146. Curtis L, Burns A. Unit Costs of Health & Social Care. Canterbury: PSSRU, University of Kent; 2020.
  147. Liangos O, Wald R, O’Bell JW, Price L, Pereira BJ, Jaber BL. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 2006;1(1):43–51. doi: 10.2215/CJN.00220605. [DOI] [PubMed]
  148. Department of Health and Social Care. Drugs and Pharmaceutical Electronic Market Information Tool (eMIT). 2021. URL: www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit (accessed 16 May 2024).
  149. National Institute for Health and Care Excellence (NICE). British National Formulary. 2021. URL: https://bnf.nice.org.uk/ (accesed 16 May 2024).
  150. World Health Organisation. WHO Collaboration Centre for Drug Statistics Methodology. 2021. URL: https://apps.who.int/whocc/Detail.aspx?Y4LL80197gk3R/zebVRpCw== (accessed 8 February 2024).
  151. Kallel H, Hergafi L, Bahloul M, Hakim A, Dammak H, Chelly H, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case–control study. Intensive Care Med 2007;33(7):1162–7. doi: 10.1007/s00134-007-0675-2. [DOI] [PubMed]
  152. Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, Wilson APR. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob Chemother 2018;73(suppl_3):iii2–78. doi: 10.1093/jac/dky027. [DOI] [PubMed]
  153. Renascience Pharma Ltd. Renapime 1g Powder for Solution for Injection/Infusion: SmPC. URL: www.medicines.org.uk/emc/product/9671/smpc (accessed 8 February 2024).
  154. National Institute for Health and Care Excellence (NICE). BNF: British National Formulary – NICE 2021. 2021. URL: https://bnf.nice.org.uk/ (accessed 16 May 2024).
  155. Department of Health and Social Care. Drugs and Pharmaceutical Electronic Market Information Tool (eMIT). 2021. URL: https://gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit (accessed 8 February 2024).
  156. National Institute for Health and Care Excellence. Antimicrobial Health Technology Evaluation: Ceftazidime with Avibactam for Treating Severe Aerobic Gram-negative Bacterial Infections: Final Scope London (National Institute for Health and Care Excellence). 2021. URL: www.nice.org.uk/about/what-we-do/life-sciences/scientific-advice/models-for-the-evaluation-and-purchase-of-antimicrobials/ceftazidime-with-avibactam (accessed 17 October 2021).
  157. Department of Health and Social Care. Impact Assessment 9553: 2018 Statutory Scheme – Branded Medicines Pricing. London, UK: Department of Health and Social Care; 2018.
  158. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. London: National Institute for Health and Care Excellence (NICE); 2013. [PubMed]
  159. EUCAST. New S, I and R Definitions. 2021. URL: www.eucast.org/newsiandr/ (accessed 16 May 2024).
  160. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. BMJ 2010;340:c2096. doi: 10.1136/bmj.c2096. [DOI] [PubMed]
  161. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis 2014;14(1):1–25. doi: 10.1186/1471-2334-14-13. [DOI] [PMC free article] [PubMed]
  162. Bakhit M, Hoffmann T, Scott AM, Beller E, Rathbone J, Del Mar C. Resistance decay in individuals after antibiotic exposure in primary care: a systematic review and meta-analysis. BMC Med 2018;16(1):1–19. doi: 10.1186/s12916-018-1109-4. [DOI] [PMC free article] [PubMed]
  163. Jeffrey B, Aanensen DM, Croucher NJ, Bhatt S. Predicting the future distribution of antibiotic resistance using time series forecasting and geospatial modelling. Wellcome Open Res 2020;5:194.
  164. Organisation for Economic Co-operation and Development. Stemming the Superbug Tide: Just a Few Dollars More. OECD, editor. URL: https://oecd.org/health/stemming-the-superbug-tide-9789264307599-en.htm (accessed 8 February 2024).
  165. Ortiz-Brizuela E, Caro-Vega Y, Bobadilla-del-Valle M, Leal-Vega F, Criollo-Mora E, Luis BL, et al. The influence of hospital antimicrobial use on carbapenem-non-susceptible Enterobacterales incidence rates according to their mechanism of resistance: a time-series analysis. J Hosp Infect 2020;105(4):757–65. doi: 10.1016/j.jhin.2020.06.019. [DOI] [PubMed]
  166. Gharbi M, Moore LS, Gilchrist M, Thomas CP, Bamford K, Brannigan ET, Holmes AH. Forecasting carbapenem resistance from antimicrobial consumption surveillance: lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit. Int J Antimicrob Agents 2015;46(2):150–6. doi: 10.1016/j.ijantimicag.2015.03.005. [DOI] [PMC free article] [PubMed]
  167. Berger P, Pascal L, Sartor C, Delorme J, Monge P, Ragon CP, et al. Generalized additive model demonstrates fluoroquinolone use/resistance relationships for Staphylococcus aureus. Eur J Epidemiol 2004;19(5):453–60. doi: 10.1023/b:ejep.0000027348.92979.94. [DOI] [PubMed]
  168. McDonnell L, Armstrong D, Ashworth M, Dregan A, Malik U, White P. National disparities in the relationship between antimicrobial resistance and antimicrobial consumption in Europe: an observational study in 29 countries. J Antimicrob Chemother 2017;72(11):3199–204. doi: 10.1093/jac/dkx248. [DOI] [PubMed]
  169. Pouwels KB, Freeman R, Muller-Pebody B, Rooney G, Henderson KL, Robotham JV, Smieszek T. Association between use of different antibiotics and trimethoprim resistance: going beyond the obvious crude association. J Antimicrob Chemother 2018;73(6):1700–7. doi: 10.1093/jac/dky031. [DOI] [PubMed]
  170. Colson AR, Megiddo I, Alvarez-Uria G, Gandra S, Bedford T, Morton A, et al. Quantifying uncertainty about future antimicrobial resistance: comparing structured expert judgment and statistical forecasting methods. PLOS ONE 2019;14(7):e0219190. doi: 10.1371/journal.pone.0219190. [DOI] [PMC free article] [PubMed]
  171. Durham L, Ge M, Cuccia A, Quinn J. Modeling antibiotic resistance to project future rates: quinolone resistance in Escherichia coli. Eur J Clin Microbiol Infect Dis 2010;29(3):353–6. doi: 10.1007/s10096-009-0862-x. [DOI] [PubMed]
  172. Goossens H, Ferech M, Vander Stichele R, Elseviers M, Group EP. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365(9459):579–87. doi: 10.1016/S0140-6736(05)17907-0. [DOI] [PubMed]
  173. Johnson AP, Muller-Pebody B, Budd E, Ashiru-Oredope D, Ladenheim D, Hain D, et al. Improving feedback of surveillance data on antimicrobial consumption, resistance and stewardship in England: putting the data at your Fingertips. J Antimicrob Chemother 2017;72(4):953–6. doi: 10.1093/jac/dkw536. [DOI] [PubMed]
  174. European Centre for Disease Prevention and Control. European Surveillance of Antimicrobial Consumption Network (ESAC-Net). 2021. URL: www.ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratory-networks/esac-net (accessed 16 May 2024).
  175. European Centre for Disease Prevention and Control. European Antimicrobial Resistance Surveillance Network (EARS-Net). 2021. URL: https://ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-net-data (accessed 16 May 2024).
  176. European Centre for Disease Prevention and Control. Antimicrobial Resistance in the EU/EEA (EARS-Net) – Annual Epidemiological Report for 2019. 2020. URL: www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2019 (accessed 16 May 2024).
  177. Morel CM, Alm RA, Årdal C, Bandera A, Bruno GM, Carrara E, et al. A one health framework to estimate the cost of antimicrobial resistance. Antimicrob Resist Infect Control 2020;9(1):1–14. doi: 10.1186/s13756-020-00822-6. [DOI] [PMC free article] [PubMed]
  178. Chatterjee A, Modarai M, Naylor NR, Boyd SE, Atun R, Barlow J, et al. Quantifying drivers of antibiotic resistance in humans: a systematic review. Lancet Infect Dis 2018;18(12):e368–78. doi: 10.1016/S1473-3099(18)30296-2. [DOI] [PubMed]
  179. Schuts EC, Boyd A, Muller AE, Mouton JW, Prins JM, editors. The effect of antibiotic restriction programs on prevalence of antimicrobial resistance: a systematic review and meta-analysis. Open Forum Infect 2021;8(4):ofab070. doi: 10.1093/ofid/ofab070. [DOI] [PMC free article] [PubMed]
  180. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 2016;387(10014):176–87. doi: 10.1016/S0140-6736(15)00473-0. [DOI] [PubMed]
  181. Enne VI, Livermore DM, Stephens P, Hall LM. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 2001;357(9265):1325–8. doi: 10.1016/S0140-6736(00)04519-0. [DOI] [PubMed]
  182. Nasrin D, Collignon PJ, Roberts L, Wilson EJ, Pilotto LS, Douglas RM. Effect of β lactam antibiotic use in children on pneumococcal resistance to penicillin: prospective cohort study. BMJ 2002;324(7328):28–30. doi: 10.1136/bmj.324.7328.28. [DOI] [PMC free article] [PubMed]
  183. European Centre for Disease Prevention and Control. Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals. Stockholm: ECDC; 2013.
  184. National Institute for Health and Care Excellence. Pneumonia in Adults: Diagnosis and Management (CG.191). 2014. URL: https://nice.org.uk/guidance/cg191 (accessed 8 February 2024).
  185. Specialist Pharmacy Service (SPS). Prescribing Outlook. Supplied by manufacturer London, UK: Speicalist Pharmacy Service; 2020.
  186. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009–11 in 14 European and Mediterranean countries. J Antimicrob Chemother 2014;69(7):1804–14. doi: 10.1093/jac/dku048. [DOI] [PubMed]
  187. Public Health England. AMR Local Indicators. 2021. URL: https://fingertips.phe.org.uk/profile/amr-local-indicators (accessed 16 May 2024).
  188. Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine). Clin Microbiol Infect 2022;28(4):521–47. doi: 10.1016/j.cmi.2021.11.025. [DOI] [PubMed]
  189. Tamma P, Aitken S, Bonomo R, Mathers A, van Duin D, Clancy C. Infectious Diseases Society of America Antimicrobial-resistant Treatment Guidance: Gram-Negative Bacterial Infections Infectious Diseases Society of America. 2022. URL: www.idsociety.org/practice-guideline/amr-guidance/#null (accessed 16 May 2024). doi: 10.1093/cid/ciad428. [DOI] [PubMed]
  190. Walker AS, White IR, Turner RM, Hsu LY, Yeo TW, White NJ, et al. Personalised randomised controlled trial designs – a new paradigm to define optimal treatments for carbapenem-resistant infections. Lancet Infect Dis 2021;21(6):e175–81. doi: 10.1016/S1473-3099(20)30791-X. [DOI] [PMC free article] [PubMed]
  191. Harnan SE, Tappenden P, Essat M, Gomersall T, Minton J, Wong R, et al. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath. Health Technol Assess 2015;19(82):1–330. doi: 10.3310/hta19820. [DOI] [PMC free article] [PubMed]
  192. Montori VM, Wilczynski NL, Morgan D, Haynes RB, Hedges T. Optimal search strategies for retrieving systematic reviews from Medline: analytical survey. BMJ 2005;330(7482):68. doi: 10.1136/bmj.38336.804167.47. [DOI] [PMC free article] [PubMed]
  193. National Institute of Health and Care Excellence. Diabetic Foot Infection: Antimicrobial Prescribing. NICE Evidence Reviews Collection. NICE: London; 2019.
  194. Li L, Smith HE, Atun R, Tudor Car L. Search strategies to identify observational studies in MEDLINE and Embase. Cochrane Database Syst Rev 2019;3(3):MR000041. doi: 10.1002/14651858.MR000041.pub2. [DOI] [PMC free article] [PubMed]
  195. Ayiku L, Levay P, Hudson T, Craven J, Barrett E, Finnegan A, Adams R. The medline UK filter: development and validation of a geographic search filter to retrieve research about the UK from OVID medline. Health Info Libr J 2017;34(3):200–16. doi: 10.1111/hir.12187. [DOI] [PubMed]
  196. Ayiku L, Levay P, Hudson T, Craven J, Finnegan A, Adams R, Barrett E. The Embase UK filter: validation of a geographic search filter to retrieve research about the UK from OVID Embase. Health Info Libr J 2019;36(2):121–33. doi: 10.1111/hir.12252. [DOI] [PubMed]
  197. Bassetti M, Rello J, Blasi F, Goossens H, Sotgiu G, Tavoschi L, et al. A systematic review on the impact of appropriate versus inappropriate initial antibiotic therapy on the outcomes of patients with severe bacterial infections. Int J Antimicrob Agents 2020;56:106184. doi: 10.1016/j.ijantimicag.2020.106184. [DOI] [PubMed]
  198. Arber M, Garcia S, Veale T, Edwards M, Shaw A, Glanville JM. Performance of Ovid Medline search filters to identify health state utility studies. Int J Technol Assess Health Care 2017;33(4):472–80. doi: 10.1017/S0266462317000897. [DOI] [PubMed]
  199. Katsube T, Wajima T, Ishibashi T, Arjona Ferreira JC, Echols R. Pharmacokinetic/pharmacodynamic modeling and simulation of cefiderocol, a parenteral siderophore cephalosporin, for dose adjustment based on renal function. Antimicrob Agents Chemother 2017;61(1):e01381–16. doi: 10.1128/AAC.01381-16. [DOI] [PMC free article] [PubMed]
  200. Zasowski EJ, Bassetti M, Blasi F, Goossens H, Rello J, Sotgiu G, et al. A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections. Chest 2020;158(3):929–38. doi: 10.1016/j.chest.2020.03.087. [DOI] [PubMed]
  201. Herkel T, Uvizl R, Doubravska L, Adamus M, Gabrhelik T, Htoutou Sedlakova M, et al. Epidemiology of Hospital-Acquired Pneumonia: Results of a Central European Multicenter, Prospective, Observational Study Compared with Data from the European Region. 2016;160(3):448–55. doi: 10.5507/bp.2016.014. [DOI] [PubMed]
  202. Pena C, Gómez-Zorrilla S, Oriol I, Tubau F, Dominguez M, Pujol M, et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur J Clin Microbiol Infect Dis 2013;32(3):413–20. doi: 10.1007/s10096-012-1758-8. [DOI] [PubMed]
  203. Amaral AC, Holder MW. Timing of antimicrobial therapy after identification of ventilator-associated condition is not associated with mortality in patients with ventilator-associated pneumonia: a cohort study. PLOS ONE 2014;9(5):e97575. doi: 10.1371/journal.pone.0097575. [DOI] [PMC free article] [PubMed]
  204. Hyndman RJ, Athanasopoulos G. Forecasting: Principles and Practice: OTexts. Melbourne, Australia: Otexts; 2018.
  205. Liboschik T, Fokianos K, Fried R. tscount: an R package for analysis of count time series following generalized linear models. J Stat Softw 2017;82(1):1–51.
  206. Aliabadi S, Anyanwu P, Beech E, Jauneikaite E, Wilson P, Hope R, et al. Effect of antibiotic stewardship interventions in primary care on antimicrobial resistance of Escherichia coli bacteraemia in England (2013–18): a quasi-experimental, ecological, data linkage study. Lancet Infect Dis 2021;21:1689–700. doi: 10.1016/S1473-3099(21)00069-4. [DOI] [PMC free article] [PubMed]
  207. Kearns B, Stevenson MD, Triantafyllopoulos K, Manca A. Generalized linear models for flexible parametric modeling of the hazard function. Med Decis Making 2019;39(7):867–78. doi: 10.1177/0272989X19873661. [DOI] [PMC free article] [PubMed]
  208. Public Health England. Escherichia coli (E. coli): Guidance, Data and Analysis. 2017. URL: https://gov.uk/government/collections/escherichia-coli-e-coli-guidance-data-and-analysis (accessed 8 February 2024).
  209. Sharland M, Pulcini C, Harbarth S, Zeng M, Gandra S, Mathur S, Magrini N; 21st WHO Expert Committee on Selection and Use of Essential Medicines. Classifying antibiotics in the WHO Essential Medicines List for optimal use – be AWaRe. Lancet Infect Dis 2018;18(1):18–20. doi: 10.1016/S1473-3099(17)30724-7. [DOI] [PubMed]
  210. Bennett Institute for Applied Data Science. OpenPrescribing.net. 2021. URL: https://openprescribing.net/ (accessed 16 May 2024).
  211. Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013;(4):CD003543. doi: 10.1002/14651858.CD003543.pub3. [DOI] [PubMed]
  212. Bhattacharya A, Hopkins S, Sallis A, Budd EL, Ashiru-Oredope D. A process evaluation of the UK-wide Antibiotic Guardian campaign: developing engagement on antimicrobial resistance. J Public Health 2017;39(2):e40–7. doi: 10.1093/pubmed/fdw059. [DOI] [PubMed]
  213. McKenzie E, Gardner Jr ES. Damped trend exponential smoothing: a modelling viewpoint. Int J Forecast 2010;26(4):661–5.
  214. Spicknall IH, Foxman B, Marrs CF, Eisenberg JN. A modeling framework for the evolution and spread of antibiotic resistance: literature review and model categorization. Am J Epidemiol 2013;178(4):508–20. doi: 10.1093/aje/kwt017. [DOI] [PMC free article] [PubMed]

RESOURCES